Loading...
•
Mar 31, 2023
Tenaya Therapeutics Q1 2023 Earnings Report
Reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.
Key Takeaways
Tenaya Therapeutics reported its first quarter 2023 financial results, highlighting progress across its business, including Fast Track designation for TN-201 and completion of dosing in the Phase 1 trial of TN-301. The company's cash position remains solid, and it anticipates achieving its 2023 development and regulatory milestones for TN-201, TN-301, and TN-401.
Received Fast Track designation from the FDA for TN-201.
Completed dosing in Phase 1 clinical trial of TN-301, with data expected in the second half of 2023.
Expanded Scientific Advisory Board with the appointments of Drs. Christine Seidman and Alex Marson.
Announced the formation of a Technical Advisory Board with expertise in gene therapy manufacturing.
Tenaya Therapeutics
Tenaya Therapeutics
Forward Guidance
Tenaya expects current cash, cash equivalents and investments in marketable securities (current and noncurrent) will be sufficient to fund the company into the first half of 2025.